Among all participants in the early phase who received the vaccine, 98.3% “sero-converted” (that is, they developed an antibody response). But how do these numbers compare with other leading vaccine candidates whose data has been released? The second method of comparison is to take into account the number of antibodies developed after people were given the Moderna and Pfizer-BioNTech vaccines. In Moderna’s case, 100% of the people developed antibodies and the levels were over twice as the levels seen in convalescent individuals. In case of the Pfizer and BioNTech inoculation too, 100% of individuals developed antibodies and this level was close to four times.

Source: Hindustan Times December 24, 2020 21:57 UTC